NASDAQ:ILMN - Illumina Stock Price, Price Target & More

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Illumina (NASDAQ:ILMN) posted its quarterly earnings results on Tuesday, April, 24th. The life sciences company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.02 by $0.43. The life sciences company had revenue of $782 million for the quarter, compared to analyst estimates of $744.30 million. Illumina had a net margin of 19.31% and a return on equity of 24.93%. The firm's revenue was up 30.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.64 earnings per share. View Illumina's Earnings History.

Illumina is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Illumina.

Illumina updated its FY18 earnings guidance on Tuesday, April, 24th. The company provided earnings per share (EPS) guidance of $4.75-4.85 for the period, compared to the Thomson Reuters consensus estimate of $4.59. The company issued revenue guidance of +15-16% to ~$3.16-3.19 billion, compared to the consensus revenue estimate of $3.14 billion.

19 equities research analysts have issued 1 year price objectives for Illumina's stock. Their forecasts range from $180.00 to $277.00. On average, they expect Illumina's stock price to reach $252.0625 in the next year. View Analyst Ratings for Illumina.

Some companies that are related to Illumina include Agilent Technologies (A), Waters (WAT), Mettler-Toledo International (MTD), Bio-Rad Laboratories, Inc. Class B (BIO.B), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Integra Lifesciences (IART), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Quanterix (QTRX), Pacific Biosciences of California (PACB), Fluidigm (FLDM) and Harvard Bioscience (HBIO).

News articles about ILMN stock have trended positive recently, according to Accern. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Illumina earned a news impact score of 0.42 on Accern's scale. They also assigned media stories about the life sciences company an impact score of 45.30 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Illumina's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (12.02%), Edgewood Management LLC (3.51%), Winslow Capital Management LLC (0.64%), Prudential Financial Inc. (0.52%), American Century Companies Inc. (0.52%) and Legal & General Group Plc (0.45%). Company insiders that own Illumina stock include A Blaine Bowman, Charles Dadswell, Christian O Henry, Daniel Bradbury, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Michel Bouchard, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Robert S Epstein and Roy A Whitfield. View Institutional Ownership Trends for Illumina.

ILMN stock was sold by a variety of institutional investors in the last quarter, including Winslow Capital Management LLC, Baillie Gifford & Co., Sei Investments Co., Swiss National Bank, Reynders McVeigh Capital Management LLC, Van ECK Associates Corp, Guggenheim Capital LLC and New York State Common Retirement Fund. Company insiders that have sold Illumina company stock in the last year include A Blaine Bowman, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karin Eastham, Marc Stapley, Michel Bouchard, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan and Robert S Epstein. View Insider Buying and Selling for Illumina.

ILMN stock was acquired by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Prudential Financial Inc., Rockefeller Capital Management L.P., Summit Trail Advisors LLC, Millennium Management LLC, Lord Abbett & CO. LLC, American Century Companies Inc. and Scout Investments Inc.. View Insider Buying and Selling for Illumina.

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ILMN stock can currently be purchased for approximately $270.83.

Illumina has a market capitalization of $39.81 billion and generates $2.75 billion in revenue each year. The life sciences company earns $726 million in net income (profit) each year or $4.00 on an earnings per share basis. Illumina employs 6,200 workers across the globe.

Illumina's mailing address is 5200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]